NCT00936195 - Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial | Biotech Hunter

Timeline

Start Date

January 31, 2010

Primary Completion Date

January 31, 2013

Study Completion Date

June 30, 2013

Conditions

HIV InfectionPregnancyBreastfeedingHIV Infections

Interventions

DRUG

Efavirenz-Tenofovir-Emtricitabine

Atripla (R) : Efavirenz 600 mg - Tenofovir 300 mg - Emtricitabine 200 mg; Dosage : 1 pill/day

DRUG

Zidovudine-Lamivudine-Lopinavir/Ritonavir

"Combivir (R) : Zidovudine 300 mg - Lamivudine 150 mg Dosage : 1 pill twice a day~Kaletra (R) or Aluvia (R) : Lopinavir 200 mg / Ritonavir 50 mg Dosage : 2 or 3 pills twice a day"

Trial Locations (2)

Unknown

Programme PAC-CI, site ANRS, Abidjan

Center for Infectious Desease Reserach in Zambia, Lusaka